DK1420827T3 - 5-CNAC sp, oralt indgivelsesmiddel for parathyroidhormonfragmenter - Google Patents
5-CNAC sp, oralt indgivelsesmiddel for parathyroidhormonfragmenterInfo
- Publication number
- DK1420827T3 DK1420827T3 DK02794796T DK02794796T DK1420827T3 DK 1420827 T3 DK1420827 T3 DK 1420827T3 DK 02794796 T DK02794796 T DK 02794796T DK 02794796 T DK02794796 T DK 02794796T DK 1420827 T3 DK1420827 T3 DK 1420827T3
- Authority
- DK
- Denmark
- Prior art keywords
- parathyroid hormone
- cnac
- oral administration
- administration agent
- hormone fragments
- Prior art date
Links
- 108090000445 Parathyroid hormone Proteins 0.000 title abstract 3
- 239000000199 parathyroid hormone Substances 0.000 title abstract 2
- 229960001319 parathyroid hormone Drugs 0.000 title abstract 2
- XRTHAPZDZPADIL-UHFFFAOYSA-N 8-[(5-chloro-2-hydroxybenzoyl)amino]octanoic acid Chemical compound OC(=O)CCCCCCCNC(=O)C1=CC(Cl)=CC=C1O XRTHAPZDZPADIL-UHFFFAOYSA-N 0.000 title 1
- 102000003982 Parathyroid hormone Human genes 0.000 title 1
- 239000003795 chemical substances by application Substances 0.000 title 1
- 239000012634 fragment Substances 0.000 title 1
- 102100036893 Parathyroid hormone Human genes 0.000 abstract 2
- 208000001132 Osteoporosis Diseases 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 230000011164 ossification Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 230000004936 stimulating effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/29—Parathyroid hormone, i.e. parathormone; Parathyroid hormone-related peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Physical Education & Sports Medicine (AREA)
- Endocrinology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Steroid Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US31304801P | 2001-08-17 | 2001-08-17 | |
| PCT/EP2002/009181 WO2003015822A1 (en) | 2001-08-17 | 2002-08-16 | 5-cnac as oral delivery agent for parathyroid hormone fragments |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK1420827T3 true DK1420827T3 (da) | 2009-12-21 |
Family
ID=23214149
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK02794796T DK1420827T3 (da) | 2001-08-17 | 2002-08-16 | 5-CNAC sp, oralt indgivelsesmiddel for parathyroidhormonfragmenter |
Country Status (26)
| Country | Link |
|---|---|
| US (4) | US20040242478A1 (ru) |
| EP (1) | EP1420827B8 (ru) |
| JP (2) | JP4959917B2 (ru) |
| KR (1) | KR20040030120A (ru) |
| CN (1) | CN1279981C (ru) |
| AT (1) | ATE443527T1 (ru) |
| AU (1) | AU2002333443C1 (ru) |
| BR (1) | BRPI0211932B1 (ru) |
| CA (1) | CA2453646C (ru) |
| CO (1) | CO5560586A2 (ru) |
| CY (1) | CY1109661T1 (ru) |
| DE (1) | DE60233803D1 (ru) |
| DK (1) | DK1420827T3 (ru) |
| EC (1) | ECSP044961A (ru) |
| ES (1) | ES2333587T3 (ru) |
| HU (1) | HUP0401441A3 (ru) |
| IL (2) | IL159714A0 (ru) |
| MX (1) | MXPA04001418A (ru) |
| NO (1) | NO328069B1 (ru) |
| NZ (1) | NZ531018A (ru) |
| PL (1) | PL210258B1 (ru) |
| PT (1) | PT1420827E (ru) |
| RU (1) | RU2322256C2 (ru) |
| SI (1) | SI1420827T1 (ru) |
| WO (1) | WO2003015822A1 (ru) |
| ZA (1) | ZA200400242B (ru) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101320817B1 (ko) * | 2001-06-01 | 2013-10-21 | 노파르티스 아게 | 부갑상선 호르몬 및 칼시토닌의 경구 투여 |
| WO2003015822A1 (en) * | 2001-08-17 | 2003-02-27 | Novartis Ag | 5-cnac as oral delivery agent for parathyroid hormone fragments |
| ATE381336T1 (de) * | 2002-04-10 | 2008-01-15 | Univ Virginia | Verwendung von a2a adenosin rezeptor agonisten und anti-pathogene mittel enthaltenden kombinationen zur behandlung von entzündungskrankheiten |
| US20050054557A1 (en) * | 2002-05-09 | 2005-03-10 | Goldberg Michael M. | Compositions for delivering parathyroid hormone and calcitonin |
| PT1651249E (pt) | 2003-07-23 | 2012-12-21 | Novartis Ag | Uso de calcitonina em osteoartrite |
| GB0427600D0 (en) * | 2004-12-16 | 2005-01-19 | Novartis Ag | Organic compounds |
| WO2006076692A1 (en) * | 2005-01-12 | 2006-07-20 | Emisphere Technologies, Inc. | Compositions for buccal delivery of parathyroid hormone |
| WO2006135915A2 (en) * | 2005-06-13 | 2006-12-21 | Rigel Pharmaceuticals, Inc. | Methods and compositions for treating degenerative bone disorders |
| CN105641686A (zh) | 2005-09-19 | 2016-06-08 | 爱密斯菲尔科技公司 | N-(5-氯水杨酰基)-8-氨基辛酸的二钠盐的晶形 |
| GB0522566D0 (en) | 2005-11-04 | 2005-12-14 | Novartis Ag | Organic compounds |
| WO2007059470A2 (en) * | 2005-11-10 | 2007-05-24 | Board Of Control Of Michigan Technological University | Black bear parathyroid hormone and methods of using black bear parathyroid hormone |
| PT2059260E (pt) * | 2006-08-31 | 2013-09-03 | Novartis Ag | Composições farmacêuticas compreendendo hgh para distribuição oral |
| CN101621991A (zh) | 2007-03-02 | 2010-01-06 | 诺瓦提斯公司 | 降钙素的口服施用 |
| AU2008318423B2 (en) | 2007-11-02 | 2013-12-05 | Emisphere Technologies, Inc. | Method of treating vitamin B12 deficiency |
| JP2013512688A (ja) | 2009-12-07 | 2013-04-18 | ミシガン テクノロジカル ユニバーシティ | クロクマの副甲状腺ホルモン及びクロクマの副甲状腺ホルモンを使用する方法 |
| WO2012130193A1 (en) | 2011-03-31 | 2012-10-04 | Zentiva, K.S. | Non-covalent soluble complexes of teriparatide with polysaccharides and a dosage form of teriparatide for oral administration |
| WO2016128971A1 (en) * | 2015-02-09 | 2016-08-18 | Entera Bio Ltd. | Treatment of bone fractures and defects |
| KR101796604B1 (ko) * | 2016-08-30 | 2017-11-10 | 목포대학교 산학협력단 | 위장관 흡수증진제를 함유하는 부갑상선 호르몬의 경구 투여 제형 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4692433A (en) * | 1983-10-12 | 1987-09-08 | The Regents Of The University Of California | Method and composition for regulating serum calcium levels of mammals |
| SK74594A3 (en) * | 1991-12-17 | 1995-01-12 | Procter & Gamble Pharma | Treatment for treating of osteoporosis |
| EP0679088B1 (en) * | 1992-09-29 | 2002-07-10 | Inhale Therapeutic Systems | Pulmonary delivery of active fragments of parathyroid hormone |
| WO1998034632A1 (en) * | 1997-02-07 | 1998-08-13 | Emisphere Technologies, Inc. | Compounds and compositions for delivering active agents |
| US5773647A (en) * | 1997-02-07 | 1998-06-30 | Emisphere Technologies, Inc. | Compounds and compositions for delivering active agents |
| AU1918300A (en) * | 1998-11-25 | 2000-06-13 | General Hospital Corporation, The | Amino-terminal modified parathyroid hormone (pth) analogs |
| CA2369591C (en) * | 1999-04-05 | 2011-06-14 | Emisphere Technologies, Inc. | Disodium salts, monohydrate, and ethanol solvates |
| ES2386263T3 (es) * | 2000-03-21 | 2012-08-14 | Emisphere Technologies, Inc. | Método de preparación de salicilamidas alquiladas mediante un producto intermedio de dicarboxilato |
| KR101320817B1 (ko) * | 2001-06-01 | 2013-10-21 | 노파르티스 아게 | 부갑상선 호르몬 및 칼시토닌의 경구 투여 |
| WO2003015822A1 (en) * | 2001-08-17 | 2003-02-27 | Novartis Ag | 5-cnac as oral delivery agent for parathyroid hormone fragments |
| EP1651248B1 (en) * | 2003-07-11 | 2009-09-09 | Novartis AG | Orally dosed pharmaceutical compositions comprising a delivery agent in micronized form |
-
2002
- 2002-08-16 WO PCT/EP2002/009181 patent/WO2003015822A1/en active Application Filing
- 2002-08-16 IL IL15971402A patent/IL159714A0/xx unknown
- 2002-08-16 CA CA002453646A patent/CA2453646C/en not_active Expired - Lifetime
- 2002-08-16 PL PL365388A patent/PL210258B1/pl unknown
- 2002-08-16 PT PT02794796T patent/PT1420827E/pt unknown
- 2002-08-16 NZ NZ531018A patent/NZ531018A/xx not_active IP Right Cessation
- 2002-08-16 DK DK02794796T patent/DK1420827T3/da active
- 2002-08-16 JP JP2003520780A patent/JP4959917B2/ja not_active Expired - Fee Related
- 2002-08-16 US US10/484,331 patent/US20040242478A1/en not_active Abandoned
- 2002-08-16 AT AT02794796T patent/ATE443527T1/de active
- 2002-08-16 KR KR10-2004-7002277A patent/KR20040030120A/ko active Search and Examination
- 2002-08-16 HU HU0401441A patent/HUP0401441A3/hu unknown
- 2002-08-16 DE DE60233803T patent/DE60233803D1/de not_active Expired - Lifetime
- 2002-08-16 MX MXPA04001418A patent/MXPA04001418A/es active IP Right Grant
- 2002-08-16 SI SI200230866T patent/SI1420827T1/sl unknown
- 2002-08-16 CN CNB028160843A patent/CN1279981C/zh not_active Expired - Fee Related
- 2002-08-16 RU RU2004107899/15A patent/RU2322256C2/ru not_active IP Right Cessation
- 2002-08-16 BR BRPI0211932A patent/BRPI0211932B1/pt not_active IP Right Cessation
- 2002-08-16 AU AU2002333443A patent/AU2002333443C1/en not_active Ceased
- 2002-08-16 ES ES02794796T patent/ES2333587T3/es not_active Expired - Lifetime
- 2002-08-16 EP EP02794796A patent/EP1420827B8/en not_active Expired - Lifetime
-
2004
- 2004-01-05 IL IL159714A patent/IL159714A/en not_active IP Right Cessation
- 2004-01-13 ZA ZA200400242A patent/ZA200400242B/en unknown
- 2004-01-29 EC EC2004004961A patent/ECSP044961A/es unknown
- 2004-02-10 NO NO20040598A patent/NO328069B1/no not_active IP Right Cessation
- 2004-02-17 CO CO04013136A patent/CO5560586A2/es not_active Application Discontinuation
-
2006
- 2006-05-30 US US11/443,528 patent/US20060217313A1/en not_active Abandoned
-
2009
- 2009-06-09 JP JP2009138067A patent/JP2009242410A/ja not_active Withdrawn
- 2009-07-01 US US12/495,966 patent/US20090264367A1/en not_active Abandoned
- 2009-11-25 CY CY20091101231T patent/CY1109661T1/el unknown
-
2011
- 2011-12-15 US US13/327,114 patent/US9272040B2/en not_active Expired - Fee Related
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK1420827T3 (da) | 5-CNAC sp, oralt indgivelsesmiddel for parathyroidhormonfragmenter | |
| MXPA03007837A (es) | Composiciones para suministrar bisfosfonatos. | |
| MXPA04008068A (es) | Metodo para administrar moleculas de glp-1. | |
| MXPA06012980A (es) | Composiciones y metodos para el suministro mucosal mejorado de la hormona paratiroidea. | |
| SI1587506T1 (sl) | Zdravljenje s kapsaicinom | |
| IL220043A0 (en) | Methods for producing ??-galactosidase a compositions | |
| ATE500218T1 (de) | Mittel zur behandlung von erkrankungen, die mit knochenschwund einhergehen, mit ep4-agonist als wirkstoff | |
| RS49756B (sr) | Primena ksenona ili smeša ksenonskog gasa za proizvodnju farmaceutskog preparata za lečenje neurointoksikacija | |
| GT199700009AA (es) | Terapia combinada para la osteoporosis | |
| LU91281I2 (fr) | Preotact-hormone parathyroïde | |
| HK1068606A1 (en) | Novel aminobenzoephenones | |
| DE60218842D1 (de) | Orale verabreichung von parathyroidhormon und calcitonin | |
| TW200511999A (en) | Pharmaceutical compositions and methods comprising combinations of 2-alkylidene-19-nor-vitamin d derivatives and parathyroid hormone | |
| NO20054034L (no) | Fremgangsmate for behandling av hypotyroidisme. | |
| UA66932C2 (en) | Complex of eletriptan and sulphobutylether-beta-cyclodextrin, pharmaceutical composition, method for their manufacture and method for treating migraine | |
| AU2003286617A8 (en) | Calcitonin drug-oligomer conjugates, and uses thereof | |
| PL370459A1 (en) | Substituted urea retinoid agonists ii | |
| MXPA03006157A (es) | Metodo de terapia de reemplazo de hormona y su forma de administracion. | |
| AU2002319223A1 (en) | Medicament for treating tumours and their metastases using a binding molecule against bone-sialoprotein | |
| TW200509960A (en) | Compositions and methods for enhanced mucosal delivery and non-infused administration of Y2 receptor-binding peptides and methods for treating and preventing obesity | |
| MXPA05003633A (es) | 2"-oxo-voruscharina y derivados de la misma. | |
| TW200519078A (en) | 2-alkylidene-19-nor-vitamin d derivatives for the treatment of a second hip fracture |